Gambaran Umum
InflaRx N.V., based in Jena, Germany, operates in the biopharmaceutical domain, primarily focusing on the development of innovative therapies for inflammatory diseases by targeting the complement system, a key element of the human immune response. The company's hallmark initiative revolves around its lead product candidate, IFX-1, an anti-C5a antibody, which shows promise across various clinical trials for treating diseases such as hidradenitis suppurativa, ANCA-associated vasculitis, and other inflammatory conditions. Furthermore, InflaRx has expanded its pipeline to explore additional compounds and targets with potential therapeutic applications in inflammatory diseases, thereby solidifying its mission to address unmet medical needs through pioneering complement-related therapeutic interventions.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk InflaRx N.V. per 2025 Jun 30 adalah 0.16 MM.
- Nilai operating income untuk InflaRx N.V. per 2025 Jun 30 adalah -52.50 MM.
- Nilai net income untuk InflaRx N.V. per 2025 Jun 30 adalah -45.29 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 0.16 | -52.50 | -45.29 |
2025-03-31 | 0.13 | -53.53 | -44.72 |
2024-12-31 | 0.17 | -53.01 | -46.06 |
2024-09-30 | 0.17 | -43.17 | -56.88 |
2024-06-30 | 0.11 | -39.73 | -46.88 |
2024-03-31 | 0.10 | -39.07 | -41.24 |
2023-12-31 | 0.06 | -44.91 | -42.67 |
2023-09-30 | 0.06 | -36.25 | -34.76 |
2023-06-30 | -34.94 | -35.23 | |
2023-03-31 | -35.71 | -26.57 | |
2022-12-31 | -32.24 | -29.48 | |
2022-09-30 | -53.97 | -34.13 | |
2022-06-30 | -56.09 | -38.26 | |
2022-03-31 | -54.57 | -53.51 | |
2021-12-31 | -47.63 | -45.63 | |
2021-09-30 | -42.81 | -41.82 | |
2021-06-30 | -36.49 | -36.62 | |
2021-03-31 | -32.09 | -31.88 | |
2020-12-31 | -33.94 | -33.98 | |
2020-09-30 | -39.61 | -38.77 |
Laporan Laba Rugi: EPS
- earnings per share basic untuk InflaRx N.V. pada 2025 Jun 30 adalah -0.73.
- laba per saham yang terdilusi untuk InflaRx N.V. pada 2025 Jun 30 adalah -0.73.
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | -0.73 | -0.73 |
2025-03-31 | -0.75 | -0.75 |
2024-12-31 | -0.78 | |
2024-09-30 | -0.97 | -0.97 |
2024-06-30 | -0.80 | -0.80 |
2024-03-31 | -0.71 | -0.71 |
2023-12-31 | -0.78 | |
2023-09-30 | -0.68 | -0.68 |
2023-06-30 | -0.74 | -0.74 |
2023-03-31 | -0.60 | -0.60 |
2022-12-31 | -0.67 | |
2022-09-30 | -0.77 | -0.77 |
2022-06-30 | -0.87 | -0.87 |
2022-03-31 | -1.21 | -1.21 |
2021-12-31 | -1.10 | |
2021-09-30 | -1.11 | -1.11 |
2021-06-30 | -1.09 | -1.09 |
2021-03-31 | -1.10 | -1.10 |
2020-12-31 | -1.26 | |
2020-09-30 | -1.46 | -1.46 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk InflaRx N.V. per 2025 Jun 30 adalah -43.12 MM.
- Nilai cash from investing activities untuk InflaRx N.V. per 2025 Jun 30 adalah 12.17 MM.
- Nilai kas dari aktivitas pendanaan untuk InflaRx N.V. per 2025 Jun 30 adalah 27.49 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -43.12 | 12.17 | 27.49 |
2025-03-31 | -47.70 | 43.08 | 27.48 |
2024-12-31 | -48.56 | 52.36 | 0.39 |
2024-09-30 | -47.54 | 53.23 | -0.39 |
2024-06-30 | -43.13 | 43.14 | -0.38 |
2024-03-31 | -42.17 | 12.83 | 52.87 |
2023-12-31 | -37.81 | -17.70 | 52.99 |
2023-09-30 | -32.15 | -18.72 | 55.29 |
2023-06-30 | -30.07 | -21.09 | 55.29 |
2023-03-31 | -31.40 | -10.71 | 2.06 |
2022-12-31 | -33.74 | 19.36 | 1.94 |
2022-09-30 | -40.25 | -16.12 | -0.31 |
2022-06-30 | -47.04 | -15.34 | -0.31 |
2022-03-31 | -42.38 | 1.58 | -0.31 |
2021-12-31 | -39.94 | -25.95 | 61.58 |
2021-09-30 | -37.94 | -0.13 | 61.52 |
2021-06-30 | -36.56 | 3.03 | 70.56 |
2021-03-31 | -36.42 | 23.03 | 71.06 |
2020-12-31 | -36.53 | 21.36 | 9.17 |
2020-09-30 | -43.01 | 52.40 | 9.18 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | ||
2024-09-30 | ||
2024-06-30 | ||
2024-03-31 | ||
2023-12-31 | ||
2023-09-30 | ||
2023-06-30 | ||
2023-03-31 | ||
2022-12-31 | ||
2022-09-30 | ||
2022-06-30 | ||
2022-03-31 | ||
2021-12-31 | ||
2021-09-30 | ||
2021-06-30 | ||
2021-03-31 | ||
2020-12-31 | ||
2020-09-30 |
Efektivitas Manajemen
- roa untuk InflaRx N.V. pada 2025 Jun 30 adalah -0.48.
- roe untuk InflaRx N.V. pada 2025 Jun 30 adalah -0.54.
- roic untuk InflaRx N.V. pada 2025 Jun 30 adalah -0.63.
- croic untuk InflaRx N.V. pada 2025 Jun 30 adalah 0.31.
- ocroic untuk InflaRx N.V. pada 2025 Jun 30 adalah -0.67.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -0.48 | -0.54 | -0.63 | 0.31 | -0.67 |
2025-03-31 | -0.43 | -0.49 | -0.74 | 0.09 | -0.78 |
2024-12-31 | -0.47 | -0.55 | -0.86 | 0.07 | -0.72 |
2024-09-30 | -0.36 | -0.40 | -0.56 | -0.00 | -0.52 |
2024-06-30 | -0.48 | -0.52 | -0.43 | 0.24 | -0.44 |
2024-03-31 | -0.42 | -0.48 | -0.41 | -0.03 | -0.36 |
2023-12-31 | -0.31 | -0.35 | -0.29 | 0.03 | -0.27 |
2023-09-30 | -0.31 | -0.34 | -0.28 | 0.03 | -0.24 |
2023-06-30 | -0.26 | -0.29 | -0.28 | 0.03 | -0.24 |
2023-03-31 | -0.26 | -0.31 | -0.33 | -0.48 | -0.39 |
2022-12-31 | -0.26 | -0.30 | -0.34 | -0.52 | -0.40 |
2022-09-30 | -0.30 | -0.33 | -0.34 | -0.52 | -0.40 |
2022-06-30 | -0.40 | -0.43 | -0.37 | -0.55 | -0.45 |
2022-03-31 | -0.31 | -0.33 | -0.55 | -0.40 | -0.44 |
2021-12-31 | -0.47 | -0.54 | -0.43 | 0.00 | -0.32 |
2021-09-30 | -0.36 | -0.41 | -0.36 | 0.22 | -0.29 |
2021-06-30 | -0.35 | -0.40 | -0.29 | 0.29 | -0.29 |
2021-03-31 | -0.28 | -0.31 | -0.23 | 0.41 | -0.26 |
2020-12-31 | -0.28 | -0.32 | -0.43 | -0.09 | -0.47 |
2020-09-30 | -0.27 | -0.31 | -0.43 | 0.20 | -0.48 |
Gross Margins
- marjin kotor untuk InflaRx N.V. pada 2025 Jun 30 adalah -22.94.
- marjin bersih untuk InflaRx N.V. pada 2025 Jun 30 adalah -344.67.
- marjin operasi untuk InflaRx N.V. pada 2025 Jun 30 adalah -412.52.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | -22.94 | -344.67 | -412.52 |
2025-03-31 | -19.01 | -277.85 | -313.71 |
2024-12-31 | -3.59 | -337.59 | -335.62 |
2024-09-30 | -9.44 | -444.47 | -496.22 |
2024-06-30 | -6.59 | -416.05 | -394.12 |
2024-03-31 | -7.44 | -676.31 | -711.82 |
2023-12-31 | -3.20 | -571.74 | -926.73 |
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1708688 |
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations |